FDA Berates Pfizer CEO’s Suggestion To Take More Paxlovid If COVID-19 Symptoms Rebound
The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.
Cardinal Health’s Shares Fall as Inflation and Supply Chain Constraints Hit Q3 Earnings
Cardinal Health Inc (NYSE:CAH) has reported Q3 FY22 adjusted EPS of $1.45, down 5% Y/Y, missing the consensus of $1.52…
Masimo Posts Better Than Expected Q1 Earnings Despite ‘Unexpected’ Supply Chain Issues
Masimo Corp’s (NASDAQ:MASI) Q1 revenue increased 1.7% Y/Y (+3.2% on a constant currency basis) to $304.2 million, beating the consensus of…
Regeneron Posts Drop In Q1 Profit As COVID Antibody Sales Hit, Shares Fall
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $11.49 per share for Q1 FY22, up 16% Y/Y, beating the $10.04 estimate. Sales increased…
Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook
Catalent Inc (NYSE:CTLT) reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging…
Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise
Teva Pharmaceutical Industries Ltd’s (NYSE:TEVA) Q1 sales reached $3.66 billion, shrinking 8% Y/Y, missing the consensus of $3.75 billion. The…
Read Why Biogen Shares Are Trading Higher After Q1 Earnings
Biogen Inc (NASDAQ:BIIB) posted Q1 sales of 2.53 billion, beating the consensus of $2.49 billion, down 6% Y/Y. Multiple sclerosis…
Here’s Why This Analyst Cut Price Target On Regeneron
RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc’s price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks…
Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters
Moderna Inc’s (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready…
Vertex Pharma’s Stem Cell Derived Diabetes Treatment Trial Put On Hold
The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) VX-880 Phase 1/2 study due to a determination that there…